Data-driven Risk Stratification and Precision Management of Pulmonary Nodules Detected on Chest Computed Tomography
Overview
Authors
Affiliations
The widespread implementation of low-dose computed tomography (LDCT) in lung cancer screening has led to the increasing detection of pulmonary nodules. However, precisely evaluating the malignancy risk of pulmonary nodules remains a formidable challenge. Here we propose a triage-driven Chinese Lung Nodules Reporting and Data System (C-Lung-RADS) utilizing a medical checkup cohort of 45,064 cases. The system was operated in a stepwise fashion, initially distinguishing low-, mid-, high- and extremely high-risk nodules based on their size and density. Subsequently, it progressively integrated imaging information, demographic characteristics and follow-up data to pinpoint suspicious malignant nodules and refine the risk scale. The multidimensional system achieved a state-of-the-art performance with an area under the curve (AUC) of 0.918 (95% confidence interval (CI) 0.918-0.919) on the internal testing dataset, outperforming the single-dimensional approach (AUC of 0.881, 95% CI 0.880-0.882). Moreover, C-Lung-RADS exhibited a superior sensitivity compared with Lung-RADS v2022 (87.1% versus 63.3%) in an independent cohort, which was screened using mobile computed tomography scanners to broaden screening accessibility in resource-constrained settings. With its foundation in precise risk stratification and tailored management, this system has minimized unnecessary invasive procedures for low-risk cases and recommended prompt intervention for extremely high-risk nodules to avert diagnostic delays. This approach has the potential to enhance the decision-making paradigm and facilitate a more efficient diagnosis of lung cancer during routine checkups as well as screening scenarios.
A new gut-brain therapeutic target for hepatic encephalopathy.
Bloom P Nat Med. 2025; 31(2):386-387.
PMID: 39920393 DOI: 10.1038/s41591-024-03467-9.
Minimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.
Afridi W, Picos S, Bark J, Stamoudis D, Vasani S, Irwin D Cancer Metastasis Rev. 2025; 44(1):29.
PMID: 39888565 PMC: 11785609. DOI: 10.1007/s10555-025-10247-5.
Avram C, Mederle A, Mavrea A, Barata P, Patrascu R Life (Basel). 2025; 15(1.
PMID: 39859954 PMC: 11767224. DOI: 10.3390/life15010014.
Mascalchi M, Marzi C, Diciotti S Signal Transduct Target Ther. 2025; 10(1):18.
PMID: 39848967 PMC: 11758031. DOI: 10.1038/s41392-024-02111-9.
Integrated multiomics signatures to optimize the accurate diagnosis of lung cancer.
Zhao M, Xue G, He B, Deng J, Wang T, Zhong Y Nat Commun. 2025; 16(1):84.
PMID: 39747216 PMC: 11695815. DOI: 10.1038/s41467-024-55594-z.